Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, and China National Center for Bioinformation, Beijing, China.
University of Chinese Academy of Sciences, Beijing, China.
Clin Infect Dis. 2020 Jul 28;71(15):713-720. doi: 10.1093/cid/ciaa203.
A novel coronavirus (CoV), severe acute respiratory syndrome (SARS)-CoV-2, has infected >75 000 individuals and spread to >20 countries. It is still unclear how fast the virus evolved and how it interacts with other microorganisms in the lung.
We have conducted metatranscriptome sequencing for bronchoalveolar lavage fluid samples from 8 patients with SARS-CoV-2, and also analyzed data from 25 patients with community-acquired pneumonia (CAP), and 20 healthy controls for comparison.
The median number of intrahost variants was 1-4 in SARS-CoV-2-infected patients, ranged from 0 to 51 in different samples. The distribution of variants on genes was similar to those observed in the population data. However, very few intrahost variants were observed in the population as polymorphisms, implying either a bottleneck or purifying selection involved in the transmission of the virus, or a consequence of the limited diversity represented in the current polymorphism data. Although current evidence did not support the transmission of intrahost variants in a possible person-to-person spread, the risk should not be overlooked. Microbiotas in SARS-CoV-2-infected patients were similar to those in CAP, either dominated by the pathogens or with elevated levels of oral and upper respiratory commensal bacteria.
SARS-CoV-2 evolves in vivo after infection, which may affect its virulence, infectivity, and transmissibility. Although how the intrahost variant spreads in the population is still elusive, it is necessary to strengthen the surveillance of the viral evolution in the population and associated clinical changes.
一种新型冠状病毒(CoV),即严重急性呼吸综合征冠状病毒 2(SARS-CoV-2),已感染超过 75000 人,并传播到 20 多个国家。目前尚不清楚该病毒的进化速度以及它与肺部其他微生物的相互作用方式。
我们对 8 例 SARS-CoV-2 感染患者的支气管肺泡灌洗液样本进行了宏转录组测序,并对 25 例社区获得性肺炎(CAP)患者和 20 例健康对照者的数据进行了分析。
SARS-CoV-2 感染患者的个体内变异中位数为 1-4 个,不同样本中变异范围为 0 至 51 个。变异在基因上的分布与人群数据中观察到的相似。然而,在人群中很少观察到个体内变异作为多态性,这意味着病毒传播过程中存在瓶颈或纯化选择,或者是当前多态性数据中所代表的多样性有限的结果。尽管目前的证据并不支持个体内变异在可能的人际传播中的传播,但不应忽视这种风险。SARS-CoV-2 感染患者的微生物群与 CAP 患者相似,要么由病原体主导,要么口腔和上呼吸道共生菌水平升高。
SARS-CoV-2 在感染后会在体内进化,这可能会影响其毒力、感染性和传染性。尽管个体内变异在人群中的传播方式仍不清楚,但有必要加强对人群中病毒进化及其相关临床变化的监测。